Refine
Year of publication
Language
- English (54)
Has Fulltext
- yes (54)
Is part of the Bibliography
- no (54)
Keywords
- BRD4 (3)
- PROTAC (3)
- Structural biology (3)
- Biochemistry (2)
- Biophysical chemistry (2)
- DYRK1A (2)
- E2F-1 (2)
- PAD4 (2)
- X-ray structure analysis (2)
- bromodomains (2)
- cancer (2)
- citrullination (2)
- epigenetic (2)
- epigenetics (2)
- immune response (2)
- inflammation (2)
- molecular docking (2)
- phenotypic screening (2)
- protein kinase inhibitor (2)
- AML (1)
- ATAD2 (1)
- ATP binding (1)
- Apoptosis (1)
- Aurora kinase (1)
- BET inhibitor (1)
- BET inhibitors (1)
- BET proteins (1)
- BH3 mimetics (1)
- BRD2 (1)
- BROMO-10 (1)
- Binding analysis (1)
- BioID (1)
- Bromodomänen (1)
- CNS melanoma (1)
- COVID-19 (1)
- CPTAC (1)
- CRBN (1)
- CRC65 (1)
- CRISPR/Cas9 (1)
- Cancer (1)
- Cas9 inhibitor (1)
- Cell biology (1)
- Cell membranes (1)
- Cell signalling (1)
- Chaperones (1)
- Chemical biology (1)
- Chemical tools (1)
- Chemische Sonden (1)
- Chlorides (1)
- Crystal structure (1)
- DNA damage (1)
- Degrader design (1)
- Differential Scanning Calorimetry (DSF) (1)
- Drug discovery (1)
- Drug screening (1)
- E. coli (1)
- E3 Ligase (1)
- ERK3 (1)
- Enzymes (1)
- Epigenetik (1)
- GABARAP (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HDAC inhibitor (1)
- High performance liquid chromatography (1)
- Hydrogen bonding (1)
- IAP (1)
- Indoles (1)
- Isothermal Titration Calorimetry (1)
- Isothermal Titration Calorimetry (ITC) (1)
- KCGS (1)
- Kd determination (1)
- Kinase inhibitors (1)
- Kinases (1)
- LC3 (1)
- LIMK1 (1)
- LIMK2 (1)
- LIR motifs (1)
- Library screening (1)
- Luciferase (1)
- MAPK6 (1)
- Mechanisms of disease (1)
- Medicinal chemistry (1)
- Medizinische Chemie (1)
- Molecular glue (1)
- NMR spectroscopy (1)
- NanoBRET (1)
- New E3-ligase ligands (1)
- PIM kinases (1)
- Phosphorylation (1)
- Rhabdomyosarcoma (1)
- SARS-CoV-2 (1)
- STK3 (1)
- Salt inducible kinase 2 (SIK2) (1)
- Small molecules (1)
- Strukturbasiertes Design (1)
- UCN-01 (1)
- ULK4 (1)
- Ubiquitin (1)
- Unc-51-like kinase (1)
- VHL (1)
- Vesicles (1)
- X-ray crystallography (1)
- accessory proteins (1)
- actin cytoskeleton dynamics (1)
- adenosine–arginine conjugate (1)
- alkaloid (1)
- androgen receptor (1)
- anilinopyrimidine (1)
- atypical MAPK kinase (1)
- autophagy (1)
- benzazepinone (1)
- biophysics (1)
- bisubstrate inhibitors (1)
- bromodomain (1)
- bromodomain inhibitor (1)
- castration-resistant prostate cancer (1)
- catalytic mechanism (1)
- cell biology (1)
- cell cycle (1)
- cell-free protein synthesis (1)
- cellular uptake and localization (1)
- chemical probes (1)
- chemical-induced proximity (1)
- chemogenomic set (1)
- chemogenomics (1)
- chromatin (1)
- chromosomal instability (1)
- co-crystal structure (1)
- co-crystallization (1)
- cofilin (1)
- combined therapy (1)
- covalent inhibitors (1)
- cytotoxicity (1)
- docking studies (1)
- drug discovery (1)
- drug response (1)
- druggable genome (1)
- dual BET/HDAC inhibitor (1)
- enhancer of transcription (1)
- epithelial cells (1)
- epithelium (1)
- evolution (1)
- fluorescent probes (1)
- forkhead box protein o1 (1)
- gastric cancer (1)
- genes (1)
- genome editing (1)
- harmine (1)
- high content imaging (1)
- indole (1)
- interaction partners (1)
- intrinsically disordered region (1)
- kinase (1)
- kinase inhibitor (1)
- kinase inhibitors (1)
- kinetically trapped state (1)
- machine learning (1)
- medicinal chemistry (1)
- mitosis (1)
- monoamine oxidase A (1)
- mouse (1)
- nephelometry (1)
- nonstructural proteins (1)
- oocytes (1)
- ovarian cancer (1)
- p63 (1)
- paclitaxel sensitization (1)
- pancreatic ductal adenocarcinoma (1)
- patient stratification (1)
- personalized medicine (1)
- phenotype (1)
- phosphorylation (1)
- protein X-ray crystallography (1)
- protein kinase (1)
- proteomics (1)
- proto-oncogene proteins c-akt (1)
- pseudokinase (1)
- quality control (1)
- resveratrol (1)
- rna (1)
- signal transduction (1)
- small molecules (1)
- small-molecule inhibitor (1)
- solubility (1)
- spindle mispositioning (1)
- spring-loaded activation (1)
- structural biolog (1)
- structural proteins (1)
- structure-based design (1)
- structure–activity relationships (1)
- sulfamide (1)
- the small molecule inhibitor MRIA9 (1)
- tp63 gene (1)
- transcription factor (1)
- understudied kinase (1)
- π-clamp (1)
Institute
- Biochemie, Chemie und Pharmazie (25)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (16)
- Pharmazie (15)
- Medizin (9)
- Biochemie und Chemie (8)
- Biowissenschaften (6)
- Exzellenzcluster Makromolekulare Komplexe (4)
- Georg-Speyer-Haus (2)
- MPI für Biophysik (2)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (2)
DNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramer
(2011)
TAp63a, a homolog of the p53 tumor suppressor, is a quality control factor in the female germline. Remarkably, already undamaged oocytes express high levels of the protein, suggesting that TAp63a’s activity is under tight control of an inhibitory mechanism. Biochemical studies have proposed that inhibition requires the C-terminal transactivation inhibitory domain. However, the structural mechanism of TAp63a inhibition remains unknown. Here, we show that TAp63a is kept in an inactive dimeric state. We reveal that relief of inhibition leads to tetramer formation with ~20-fold higher DNA affinity. In vivo, phosphorylation-triggered tetramerization of TAp63a is not reversible by dephosphorylation. Furthermore, we show that a helix in the oligomerization domain of p63 is crucial for tetramer stabilization and competes with the transactivation domain for the same binding site. Our results demonstrate how TAp63a is inhibited by complex domain-domain interactions that provide the basis for regulating quality control in oocytes.
The P300/CBP-associated factor plays a central role in retroviral infection and cancer development, and the C-terminal bromodomain provides an opportunity for selective targeting. Here, we report several new classes of acetyl-lysine mimetic ligands ranging from mM to low micromolar affinity that were identified using fragment screening approaches. The binding modes of the most attractive fragments were determined using high resolution crystal structures providing chemical starting points and structural models for the development of potent and selective PCAF inhibitors.
Bromodomain-containing protein 4 (BRD4) is a member of the bromo- and extraterminal (BET) domain-containing family of epigenetic readers which is under intensive investigation as a target for anti-tumor therapy. BRD4 plays a central role in promoting the expression of select subsets of genes including many driven by oncogenic transcription factors and signaling pathways. However, the role of BRD4 and the effects of BET inhibitors in non-transformed cells remain mostly unclear. We demonstrate that BRD4 is required for the maintenance of a basal epithelial phenotype by regulating the expression of epithelial-specific genes including TP63 and Grainy Head-like transcription factor-3 (GRHL3) in non-transformed basal-like mammary epithelial cells. Moreover, BRD4 occupancy correlates with enhancer activity and enhancer RNA (eRNA) transcription. Motif analyses of cell context-specific BRD4-enriched regions predicted the involvement of FOXO transcription factors. Consistently, activation of FOXO1 function via inhibition of EGFR-AKT signaling promoted the expression of TP63 and GRHL3. Moreover, activation of Src kinase signaling and FOXO1 inhibition decreased the expression of FOXO/BRD4 target genes. Together, our findings support a function for BRD4 in promoting basal mammary cell epithelial differentiation, at least in part, by regulating FOXO factor function on enhancers to activate TP63 and GRHL3 expression.
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer.
Mammalian oocytes are arrested in the dictyate stage of meiotic prophase I for long periods of time, during which the high concentration of the p53 family member TAp63α sensitizes them to DNA damage-induced apoptosis. TAp63α is kept in an inactive and exclusively dimeric state but undergoes rapid phosphorylation-induced tetramerization and concomitant activation upon detection of DNA damage. Here we show that the TAp63α dimer is a kinetically trapped state. Activation follows a spring-loaded mechanism not requiring further translation of other cellular factors in oocytes and is associated with unfolding of the inhibitory structure that blocks the tetramerization interface. Using a combination of biophysical methods as well as cell and ovary culture experiments we explain how TAp63α is kept inactive in the absence of DNA damage but causes rapid oocyte elimination in response to a few DNA double strand breaks thereby acting as the key quality control factor in maternal reproduction.
Peptidyl arginine deiminase 4 (PAD4) is a nuclear enzyme that converts arginine residues to citrulline. Although increasingly implicated in inflammatory disease and cancer, the mechanism of action of PAD4 and its functionally relevant pathways remains unclear. E2F transcription factors are a family of master regulators that coordinate gene expression during cellular proliferation and diverse cell fates. We show that E2F-1 is citrullinated by PAD4 in inflammatory cells. Citrullination of E2F-1 assists its chromatin association, specifically to cytokine genes in granulocyte cells. Mechanistically, citrullination augments binding of the BET (bromodomain and extra-terminal domain) family bromodomain reader BRD4 (bromodomain-containing protein 4) to an acetylated domain in E2F-1, and PAD4 and BRD4 coexist with E2F-1 on cytokine gene promoters. Accordingly, the combined inhibition of PAD4 and BRD4 disrupts the chromatin-bound complex and suppresses cytokine gene expression. In the murine collagen-induced arthritis model, chromatin-bound E2F-1 in inflammatory cells and consequent cytokine expression are diminished upon small-molecule inhibition of PAD4 and BRD4, and the combined treatment is clinically efficacious in preventing disease progression. Our results shed light on a new transcription-based mechanism that mediates the inflammatory effect of PAD4 and establish the interplay between citrullination and acetylation in the control of E2F-1 as a regulatory interface for driving inflammatory gene expression.
Peptidyl arginine deiminase 4 (PAD4) is a nuclear enzyme that converts arginine residues to citrulline. Although increasingly implicated in inflammatory disease and cancer, the mechanism of action of PAD4 and its functionally relevant pathways remains unclear. E2F transcription factors are a family of master regulators that coordinate gene expression during cellular proliferation and diverse cell fates. We show that E2F-1 is citrullinated by PAD4 in inflammatory cells. Citrullination of E2F-1 assists its chromatin association, specifically to cytokine genes in granulocyte cells. Mechanistically, citrullination augments binding of the BET (bromodomain and extra-terminal domain) family bromodomain reader BRD4 (bromodomain-containing protein 4) to an acetylated domain in E2F-1, and PAD4 and BRD4 coexist with E2F-1 on cytokine gene promoters. Accordingly, the combined inhibition of PAD4 and BRD4 disrupts the chromatin-bound complex and suppresses cytokine gene expression. In the murine collagen-induced arthritis model, chromatin-bound E2F-1 in inflammatory cells and consequent cytokine expression are diminished upon small-molecule inhibition of PAD4 and BRD4, and the combined treatment is clinically efficacious in preventing disease progression. Our results shed light on a new transcription-based mechanism that mediates the inflammatory effect of PAD4 and establish the interplay between citrullination and acetylation in the control of E2F-1 as a regulatory interface for driving inflammatory gene expression.
The p300/CBP‐associated factor (PCAF) and related GCN5 bromodomain‐containing lysine acetyl transferases are members of subfamily I of the bromodomain phylogenetic tree. Iterative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine‐based L‐45 (dubbed L‐Moses) as the first potent, selective, and cell‐active PCAF bromodomain (Brd) inhibitor. Synthesis from readily available (1R,2S)‐(−)‐norephedrine furnished L‐45 in enantiopure form. L‐45 was shown to disrupt PCAF‐Brd histone H3.3 interaction in cells using a nanoBRET assay, and a co‐crystal structure of L‐45 with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. Compound L‐45 shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell‐permeability, and metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use.
Serine/arginine-protein kinase 1 (SRPK1) regulates alternative splicing of VEGF-A to pro-angiogenic isoforms and SRPK1 inhibition can restore the balance of pro/antiangiogenic isoforms to normal physiological levels. The lack of potency and selectivity of available compounds has limited development of SRPK1 inhibitors, with the control of alternative splicing by splicing factor-specific kinases yet to be translated. We present here compounds that occupy a binding pocket created by the unique helical insert of SRPK1, and trigger a backbone flip in the hinge region, that results in potent (<10 nM) and selective inhibition of SRPK1 kinase activity. Treatment with these inhibitors inhibited SRPK1 activity and phosphorylation of serine/arginine splicing factor 1 (SRSF1), resulting in alternative splicing of VEGF-A from pro-angiogenic to antiangiogenic isoforms. This property resulted in potent inhibition of blood vessel growth in models of choroidal angiogenesis in vivo. This work identifies tool compounds for splice isoform selective targeting of pro-angiogenic VEGF, which may lead to new therapeutic strategies for a diversity of diseases where dysfunctional splicing drives disease development.
Two missense mutations of the DYRK1B gene have recently been found to co-segregate with a rare autosomal-dominant form of metabolic syndrome. This gene encodes a member of the DYRK family of protein kinases, which depend on tyrosine autophosphorylation to acquire the catalytically active conformation. The mutations (H90P and R102C) affect a structural element named DYRK homology (DH) box and did not directly interfere with the conformation of the catalytic domain in a structural model of DYRK1B. Cellular assays showed that the mutations did not alter the specific activity of mature kinase molecules. However, a significant part of the mutant DYRK1B protein accumulated in detergent-insoluble cytoplasmic aggregates and was underphosphorylated on tyrosine. The mutant DYRK1B variants were more vulnerable to the HSP90 inhibitor ganetespib and showed enhanced binding to the co-chaperone CDC37 as compared to wild type DYRK1B. These results support the hypothesis that the mutations in the DH box interfere with the maturation of DYRK1B by tyrosine autophosphorylation and compromise the conformational stability of the catalytic domain, which renders the kinase susceptible to misfolding.